Tango Therapeutics (TNGX) Operating Expenses (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly Operating Expenses of $12.0 million for Q1 2026, up 35.74% year-over-year from $8.8 million in Q1 2025, and down 71.38% quarter-over-quarter from $41.9 million in Q4 2025.
Tango Therapeutics (TNGX) Operating Expenses (2020 - 2026) Analysis & Trends
Tango Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $12.0 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 35.74% year-over-year to $12.0 million; the TTM figure through Mar 2026 stood at $137.7 million (down 40.84% YoY), while the FY2025 annual figure was $173.7 million, down 7.46% from the prior year.
- Operating Expenses for Q1 2026 stood at $12.0 million, down from $41.9 million in the prior quarter.
- The five-year high for Operating Expenses was $167.1 million in Q4 2024, with the low at $7.5 million in Q3 2024.
- The 5-year median for Operating Expenses is $37.0 million (2022), against an average of $41.5 million.
- Peak annual rise in Operating Expenses reached 429.08% in 2025, while the deepest fall reached 81.89% in 2025.
- Tango Therapeutics' Operating Expenses stood at $37.0 million in 2022, then increased by 9.37% to $40.4 million in 2023, then jumped by 313.07% to $167.1 million in 2024, then plunged by 74.94% to $41.9 million in 2025, then sank by 71.38% to $12.0 million in 2026.
- Business Quant data shows TNGX's Operating Expenses at $12.0 million in Q1 2026, $41.9 million in Q4 2025, and $39.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | 59.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.79 Mn |
| Mar 31, 2026 | 11.98 Mn |
| Dec 31, 2025 | 41.86 Mn |
| Sep 30, 2025 | 39.74 Mn |
| Jun 30, 2025 | 44.15 Mn |
| Mar 31, 2025 | 8.83 Mn |
| Dec 31, 2024 | 167.06 Mn |
| Sep 30, 2024 | 7.51 Mn |
| Jun 30, 2024 | 49.43 Mn |
| Mar 31, 2024 | 48.73 Mn |
| Dec 31, 2023 | 40.44 Mn |
| Sep 30, 2023 | 36.36 Mn |
| Jun 30, 2023 | 37.85 Mn |
| Mar 31, 2023 | 36.05 Mn |
| Dec 31, 2022 | 36.98 Mn |
| Sep 30, 2022 | 36.84 Mn |
| Jun 30, 2022 | 30.97 Mn |
| Mar 31, 2022 | 31.14 Mn |
| Dec 31, 2021 | 27.70 Mn |
| Sep 30, 2021 | 26.36 Mn |